Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial
Peter C Kahr, Fabian aus dem Siepen, Olivier Lairez, Erwan Donal, Thibaud Damy, Arnt V Kristen, Cristina C Quarta, Michele F Mercuri, Sarah Keppner-Witter, Eva Herrmann-Keiner, Mia Tichy, Aubin Michalon, Jan Grimm, Roger M Nitsch, Christoph Hock, Pablo Garcia-Pavia, Peter van der Meer · 2026
Read Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial by Peter C Kahr, Fabian aus dem Siepen, Olivier Lairez, Erwan Donal, Thibaud Damy, Arnt V Kristen, Cristina C Quarta, Michele F Mercuri, Sarah Keppner-Witter, Eva Herrmann-Keiner, Mia Tichy, Aubin Michalon, Jan Grimm, Roger M Nitsch, Christoph Hock, Pablo Garcia-Pavia, Peter van der Meer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13375531.txt.
Description
Peter C Kahr and co-authors give long-term news on a heart protein drug in a 2026 study. The drug is a lab-made immune tag that seeks stray protein laid in the heart wall. In the first human trial it was safe and cut marks of that load over one year.
A group of 23 men from that trial kept on with the drug in an open next phase. They got a mean of ten more drips, for a top of 24 in all. Most also took a pill that steadies the same protein. Long checks of heart shape, marks, and harms will tell if load cuts turn to real gains.
Catalog record
| CREATOR | Peter C Kahr, Fabian aus dem Siepen, Olivier Lairez, Erwan Donal, Thibaud Damy, Arnt V Kristen, Cristina C Quarta, Michele F Mercuri, Sarah Keppner-Witter, Eva Herrmann-Keiner, Mia Tichy, Aubin Michalon, Jan Grimm, Roger M Nitsch, Christoph Hock, Pablo Garcia-Pavia, Peter van der Meer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60221 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |